Equillium, Inc. (NASDAQ:EQ) Short Interest Up 245.6% in January

by · The Markets Daily

Equillium, Inc. (NASDAQ:EQ – Get Free Report) was the recipient of a significant growth in short interest in January. As of January 31st, there was short interest totalling 93,300 shares, a growth of 245.6% from the January 15th total of 27,000 shares. Approximately 0.5% of the company’s stock are short sold. Based on an average daily volume of 771,800 shares, the short-interest ratio is presently 0.1 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Equillium stock. Takeda Pharmaceutical Co. Ltd. acquired a new stake in Equillium, Inc. (NASDAQ:EQ – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 1,824,977 shares of the company’s stock, valued at approximately $1,369,000. Equillium comprises about 5.2% of Takeda Pharmaceutical Co. Ltd.’s investment portfolio, making the stock its 4th largest holding. Takeda Pharmaceutical Co. Ltd. owned 5.15% of Equillium as of its most recent filing with the SEC. 27.05% of the stock is owned by institutional investors and hedge funds.

Equillium Stock Performance

Shares of NASDAQ:EQ traded down $0.02 during trading on Thursday, hitting $0.85. The company’s stock had a trading volume of 68,797 shares, compared to its average volume of 1,572,149. Equillium has a fifty-two week low of $0.49 and a fifty-two week high of $3.25. The business has a 50 day moving average price of $0.70 and a two-hundred day moving average price of $0.81. The company has a market capitalization of $30.26 million, a PE ratio of -6.09 and a beta of 1.79.

Equillium Company Profile

(Get Free Report)

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.

Read More